This Biotech Could Be the First of Its Kind to Reach Phase III

finviz dynamic chart for  MNMD

MindMed (MNMD) is a psychedelic medicine and therapy developer.

With the rise in mental health issues, and the growing awareness surrounding them, the company is working to cure depression, fight off alcoholism, and help people end their addictions to other, more dangerous, drugs out on the market. 

Published research and studies show that psychedelics have the potential to help individuals suffering from major diseases ranging from Alzheimer’s to schizophrenia as well. 

And with more active trials than any other biotech company in the space, the firm is making significant progress in creating psychedelic treatments for clinical use. Currently, it has several Phase I and Phase II trials active. 

So far, no psychedelic treatment has made it to Phase III. This means that if MNMD makes any breakthrough, it could see a surge in share value in the coming years. 

Still, with MNMD trading as a penny stock on the Nasdaq, there are risks to investing in the company. But with those risks, come massive potential gains.

Patent-Hoarding Company Holds Tech Industry HOSTAGE With $4 SuperStock

Sponsored

Most companies file for a patent and wait years to proceed with business…

But not these guys.

In fact, they own exactly 45,599 global patents…

And now EVERY major tech company is forced to do business with them.

The crazy thing is…

Their stock is trading for only $4 a share going into 2022…

And almost NOBODY knows how to invest in it because it trades under a secret name.

This information wasn't supposed to get out.

These guys are set to make a huge deal with Apple…

And it's only a matter of time before word gets out and people start jumping on the bandwagon.

Click Here to See Why One Market Expert is Calling This a “Single-Stock Retirement Play.

$3.73 EV Stock No One's Talking About

This company is a sneaky EV play that no one’s talking about.

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

$30 Stock Freaking Out Billionaires

This stock is an industry leader in a robotics technology that is freaking out billionaires (trading for just $30).

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

The Best TaaS Stock Right Now

This company is set to corner the market in a self-driving technology that  could fundamentally change our entire society – much like the internet did.

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

Up to 20,000 IPOs All in One Day

A radical $2.1 quadrillion shift is coming to the financial markets.

Some are calling it G.T.E. and Mark Cuban, Elon Musk, Richard Branson, and even banks like J.P. Morgan are invested in the tech behind it.

Just $25 could get you in alongside these billionaires. 

Enter your email address to receive the video that reveals it all.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

53-cent Biotech Stock with $2 Price Target

Steve Cohen, the billionaire stock picker known for running one of the most successful hedge funds ever, has poured millions into the first stock, and it’s trading for only 53 cents.

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works